FDA approves Ariad's Iclusig for rare leukemias

12/16/2012 | Fox Business · HealthDay News

Ariad Pharmaceuticals obtained accelerated FDA approval for Iclusig, or ponatinib, to treat patients with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. The drug, which was cleared three months ahead of schedule, inhibits certain proteins that promote cancer cell development. Iclusig will be sold with a boxed warning on its label about the risk of blood clots and liver poisoning.

View Full Article in:

Fox Business · HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD